1160838-31-2

Basic information

• Product Name: butyl (E)-3-(4-amino-3-(methylamino)phenyl)acrylate
• Synonyms: butyl (E)-3-(4-amino-3-(methylamino)phenyl)acrylate
• CAS NO: 1160838-31-2
• Molecular Weight: 248.325
• Mol File: 1160838-31-2.mol

Chemical Properties

• CAS DataBase Reference: butyl (E)-3-(4-amino-3-(methylamino)phenyl)acrylate(CAS DataBase Reference)
• NIST Chemistry Reference: butyl (E)-3-(4-amino-3-(methylamino)phenyl)acrylate(1160838-31-2)
• EPA Substance Registry System: butyl (E)-3-(4-amino-3-(methylamino)phenyl)acrylate(1160838-31-2)

Safety Data

• Hazardous Substances Data: 1160838-31-2(Hazardous Substances Data)

Upstream product

• 1370023-74-7 n-butyl 3-methylamino-4-nitrocinnamate 
• 141-32-2 acrylic acid n-butyl ester 
• 863886-03-7 n-butyl (E)-3-[4-nitro-3-(methylamino)phenyl]prop-2-enoate 
• 611-06-3 2,4-dichloronitrobenzene 
• 35966-84-8 4-chloro-2-methylaminonitrobenzene 

Downstream Products

• 1370023-80-5 (E)-3-(2-(1-(2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido)cyclobutyl)-1-methyl-1H-benzo[d]imidazol-6-yl)acrylic acid sodium salt 
• 1461641-21-3 (E)-3-[2-(1-{[2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carbonyl]amino}cyclobutyl)-3-methyl-3H-benzimidazol-5-yl]acrylic acid 
• 1370023-77-0 C₂₄H₃₅N₃O₅ 

Relevant articles and documents

Synthesis of deleobuvir, a potent hepatitis C virus polymerase inhibitor, and its major metabolites labeled with carbon-13 and carbon-14

Deleobuvir, (2E)-3-(2-{1-[2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carboxamido]cyclobutyl}-1-methyl-1H-benzimidazol-6-yl)prop-2-enoic acid (1), is a non-nucleoside, potent, and selective inhibitor of hepatitis C virus NS5B polymerase.

MESYLATE SALT FORMS OF A POTENT HCV INHIBITOR

This invention relates to novel mesylate salt forms of the following Compound (1), and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in methods for the treatment of Hepatitis C Viral (HCV) infection:

ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE POPULATIONS

The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) Compound (2), or a pharmaceutically acceptable salt thereof, as herein described, and optionally (c) ribavirin, and methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient that has genetic variations located near the IL28B gene, including SNP rs 12979860 with a CC or non-CC genotype and SNP rs 8099917 with a TT or non-TT genotype.

SOLID STATE FORMS OF A POTENT HCV INHIBITOR

This invention relates to novel sodium salt forms of the following Compound (1), and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection.

VIRAL POLYMERASE INHIBITORS

An enantiomer, diastereoisomer or tautomer of a compound, represented by formula (I): wherein either A or B is nitrogen and the other B or A is C, and the radicals R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein, or a salt or ester thereof as viral polymerase inhibitors. The compound is used as an inhibitor of RNA dependent RNA polymerases, particularly those viral polymerases within the Flaviviridae family, more particularly to HCV polymerase.